vx680 has been researched along with Breast-Neoplasms* in 2 studies
2 other study(ies) available for vx680 and Breast-Neoplasms
| Article | Year |
|---|---|
Novel Aurora A and Protein Kinase C (α, β1, β2, and θ) Multitarget Inhibitors: Impact of Selenium Atoms on the Potency and Selectivity.
Aurora kinases and protein kinase C (PKC) have been shown to be involved in different aspects of cancer progression. To date, no dual Aurora/PKC inhibitor with clinical efficacy and low toxicity is available. Here, we report the identification of compound Topics: Antineoplastic Agents; Aurora Kinase A; Breast Neoplasms; Cell Line, Tumor; Drug Screening Assays, Antitumor; Female; Humans; Hydrogen Bonding; Isoenzymes; Molecular Docking Simulation; Protein Kinase C; Protein Kinase Inhibitors; Selenium Compounds; Small Molecule Libraries; Structure-Activity Relationship; Substrate Specificity; Tumor Stem Cell Assay | 2022 |
Design, synthesis, and biological evaluation of novel pyrazolo [3,4-d]pyrimidine derivatives as potent PLK4 inhibitors for the treatment of TRIM37-amplified breast cancer.
Serine/threonine-protein kinase polo-like kinase 4 (PLK4) is a mitosis-associated protein kinase that plays a vital role in the duplication of centrioles in dividing cells and is considered a promising target of synthetic lethality in TRIM37-amplified breast cancer. Herein, based on a rational drug design strategy, we described a series of pyrazolo [3,4-d]pyrimidine derivatives as potent PLK4 inhibitors and dissected the relevant structure-activity relationships (SARs). Most compounds showed potent suppressive activities against PLK4, with IC Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Female; Humans; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrimidines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Tripartite Motif Proteins; Ubiquitin-Protein Ligases | 2022 |